Tag:

Valeant

Latest Headlines

Latest Headlines

Drug price increases hit record for Q2, with no sign of slowdown, analysts say

We've heard plenty of anecdotal reports about expensive drugs, from the long-running brouhaha over Gilead Sciences' hepatitis C drugs to the consternation about pricey new cancer meds. But occasionally, there's a broader view--and not surprisingly, that shows some impressive price inflation, too.

Valeant can have Zoetis, Bayer says. We have our hands full already

Whether animal health leader Zoetis receives any more buyout offers after Valeant's reported approach remains to be seen. But if it does, Bayer's leaders insist a competing bid won't be coming from them.

Can Valeant keep its debt-fueled M&A binge going strong enough? That's the question

Serial dealmaker Valeant seems to have bounced back since its failed bid for Allergan in November. The Canadian pharma has since inked two deals and is rumored to have another one in the works.

Valeant said to step up talks on potential $800M deal for Egypt's Amoun

Last month, reports said Valeant was eyeing up one of Egypt's largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in the coming weeks.

Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA

Last week, the FDA approved both Valeant's Xifaxan and Actavis' new Viberzi to treat IBS-D. And now, the market will get to watch what Bernstein analyst Ronny Gal deemed an "interesting test" of two company approaches as the pair competes for uptake.

GI dealmaking pays off for Valeant, Actavis with same-day FDA nods in IBS

When it comes to go-aheads in irritable bowel syndrome, the FDA was busy Wednesday, approving the indication for a pair of drugs. And now, it looks as if recent M&A moves to acquire those drugs are about to pay off for Valeant and Actavis.

Actavis and Valeant go head-to-head on IBS as FDA OKs 2 new drugs

A little more than a year after Forest Labs bought out Furiex and its experimental irritable bowel syndrome drug eluxadoline in a $1.5 billion deal, Brent Saunders and Forest-buyer Actavis have scored an FDA approval that should surprise no one. And the agency paired the approval with a green light for Valeant's Xifaxan (rifaximin) in IBS, another drug that's been changing hands lately in the frenzy of M&A deals that has been changing the face of the industry.

Valeant chief Pearson won't be scared off by M&A 'bubble'

Valeant CEO J. Michael Pearson is plenty familiar with the pharma M&A space; after all, he's made scores of deals since taking up the post in 2008. And the way he sees it, with pickups happening left and right in the sector, some of pharma's recent acquisitions "are not going to work."

Report: Valeant in talks to buy Egypt's Amoun for up to $800M

Valeant's next pickup could come from the Middle East, where it's reportedly in deal talks with one of Egypt's largest drugmakers, Amoun.

Heavyweight investors sock big bucks into Valeant while others sell down

Valeant's former deal partner Bill Ackman is pretty rosy on his outlook for the company, as he's shown with a large share-grab and comparison to Warren Buffett's Berkshire Hathaway. But he's not the only one.